Identification of Genetic Alteration of TP53 Gene in Uterine Carcinosarcoma through Oncogenomic Approach
Keywords:
TP53, Uterine Carcinosarcoma, Insilco, Mutations, OncoprintAbstract
Uterine Carcinosarcoma is the most common and aggressive disease in women. Great efforts have been undertaken in search of treatment for Uterine Carcinosarcoma. Mutations in TP53 gene are associated with progression and development of Uterine Carcinosarcoma. In this study genetic alterations of TP53 in uterine carcinosarcoma cases were identified using cbioportal plate form (http://www.cbioportal.org/). Outcome of our study showed 91% mutation of TP53 in uterine carcinosarcoma. Co-expression analysis showed that MPDU1 gene expression is positively correlated with expression of TP53 gene (p=4.287e-6, q=0.0643). Network view analysis revealed TP53 to be closely associated with RB1. It is concluded that TP53 could be effective target for uterine carcinosarcoma therapy and drug designing.
References
K. Matsuo et al., “Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma,” Ann. Oncol., vol. 27, no. 7, pp. 1257–1266, 2016
K. Matsuo et al., “Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma,” Gynecol. Oncol., vol. 145, no. 1, pp. 78–87, 2017
F. Amant et al., “Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer,” Gynecol. Oncol., vol. 98, no. 2, pp. 274–280, 2005.
Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence—SEER 9 Regs Public-Use, Nov 2004 Sub (1973–2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005, based on the November 2004 submission.
M. Callister et al., “Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome,” Int. J. Radiat. Oncol. Biol. Phys., vol. 58, no. 3, pp. 786–796, 2004.
G. Sutton, “Uterine sarcomas 2013.,” Gynecol. Oncol., vol. 130, no. 1, pp. 3–5, Jul.2013.
S. E. Brooks et al., “Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989--1999,” Gynecol. Oncol., vol. 93, no. 1, pp. 204–208, 2004
R. F. Meredith et al., “An excess of uterine sarcomas after pelvic irradiation,” Cancer, vol. 58, no. 9, pp. 2003–2007, 1986.
W. G. McCluggage et al., “Uterine carcinosarcoma in association with tamoxifen therapy.,” Br. J. Obstet. Gynaecol., vol. 104, no. 6, pp. 748–750, Jun. 1997.
K. Matsuo et al., “Tumor characteristics and survival outcomes of women with tamoxifen-related uterine carcinosarcoma,” Gynecol. Oncol., vol. 144, no. 2, pp. 329– 335, 2017.
S. H. Shah et al., “Uterine sarcomas: then and now,” Am. J. Roentgenol., vol. 199, no. 1, pp. 213–223, 2012.
C. Pacaut et al., “Uterine and Ovary Carcinosarcomas,” Am. J. Clin. Oncol., vol. 38, no. 3, pp. 272–277, 2015.
A. D. Cherniack et al., “Integrated molecular characterization of uterine carcinosarcoma,” Cancer Cell, vol. 31, no. 3, pp. 411–423, 2017.
P. Chène, “Inhibiting the p53--MDM2 interaction: an important target for cancer therapy,” Nat. Rev. cancer, vol. 3, no. 2, p. 102, 2003.
